Spondyloarthritis-associated IgA nephropathy

Abstract Introduction IgA nephropathy (IgAN) can be associated with spondyloarthritis (SpA). The course of SpA-associated IgAN remains largely unknown due to the absence of large cohorts Methods This retrospective study included patients with biopsy-proven IgAN and definite SpA. Kidney biopsies were centrally examined and scored according to the IgAN Oxford Classification. Thirty-two patients fulfilled the inclusion criteria, with an M/F ratio of 9/1 and median age of 27 and 37 years at SpA and IgAN diagnosis, respectively. HLA-B27 was positive in 90% of cases, and most patients (60%) presented with ankylosing spondylitis. The mean baseline eGFR was 84±26 ml/min/1.73 m2, and the urine protein-to-creatinine ratio was 0.19 g/mmol Results Renal biopsy revealed frequent presence of crescents (33%) and interstitial inflammation (18%). Despite almost constant use of RAS inhibitors, combined with steroids in 13/32 patients, renal outcome was particularly poor. After a median follow-up of 5.9 years, 4 patients (12.5%) reached end-stage renal disease and 41% of patients experienced a >50% decrease of eGFR. The mean annual eGFR decline rate was -4.3 ± 6.7 ml/min/1.73 m2. The risk of reaching class IV or V CKD stage during follow-up was associated with the presence of hypertension, level of proteinuria, and baseline S- and T-scores of the Oxford Conclusion SpA-associated IgAN is associated with a poor renal outcome, despite frequent use of steroids. TNF-α blockade did not appear to influence the rate of eGFR decline in this setting.